Oxford BioMedica Enters Gene Therapy Collaboration with Bioverativ Worth up to $105M

Rare Daily Staff

Oxford BioMedica entered into a collaboration and license agreement worth up to $105 million with Bioverativ for the development and manufacturing of lentiviral vectors to treat hemophilia.

The agreement includes a license to use Oxford’s LentiVector-enabled technology and access to its industrial-scale manufacturing technology. 

Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ. Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ’s lentiviral vector hemophilia products.

Bioverativ will also fund process development and scale-up activities for its lentiviral vector hemophilia products at Oxford BioMedica. The agreement also allows for the parties to put in place a clinical supply agreement for GMP manufacturing of hemophilia products at Oxford BioMedica.

“Bioverativ’s investment in hemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy,” said John Dawson, CEO of Oxford BioMedica. “This new deal, potentially worth in excess of $100 million, demonstrates Oxford BioMedica’s strategy of building multiple partnerships with leaders in their therapeutic categories and will support the group’s continued growth.”

February 15, 2018
Photo: John Dawson, CEO of Oxford BioMedica